- Looking at CER from the pharmaceutical industry perspectiveRobert W Dubois
NationalPharmaceutical Council, Washington, DC 20006, USA
J Manag Care Pharm 18:S9-12. 2012..But the growth of CER also brings an array of questions and decisions for purchasers and policy makers that will not be easy to answer and which require significant dialogue to fully understand and address...
- Setting priorities for comparative effectiveness research: from assessing public health benefits to being open with the publicRobert W Dubois
National Pharmaceutical Council, Washington, DC, USA
Health Aff (Millwood) 30:2235-42. 2011..We also recommend that during the priority-setting process, there should be transparent conversations among those who make decisions about the priorities and the public...